DNASE1 and breast cancer: The supplementation of BC plasma with rhDNaseI restored the ability to degrade NETs, which indicates that impaired NET degradation in BC patients is not due to DNaseI inhibitors or anti-NET antibodies as in some systemic lupus erythematosus patients (36), but a consequence of reduced levels of plasma DNaseI.